{"symbol":"ABBV","provider":"yahoo-finance","fetchedAt":"2025-12-24T01:49:09.493Z","asOfDate":"2025-12-23","articles":[{"id":"51c22cfd-2655-30f7-8e08-df4b73fd6e3a","title":"ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?","url":"https://finance.yahoo.com/news/abbv-vs-azn-pharma-stock-155100815.html","publisher":"Zacks","publishedAt":"2025-12-23T15:51:00.000Z","relatedTickers":["AZN"],"mainIdea":"ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?","summary":"Zacks: ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?. AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge. Related tickers mentioned: AZN."},{"id":"365f8e8a-12dd-3afc-b85f-9a89dded47c3","title":"5 Big Drug Stocks That May Continue to Outperform in 2026","url":"https://finance.yahoo.com/news/5-big-drug-stocks-may-134800671.html","publisher":"Zacks","publishedAt":"2025-12-23T13:48:00.000Z","relatedTickers":["JNJ","LLY","^GSPC"],"mainIdea":"5 Big Drug Stocks That May Continue to Outperform in 2026","summary":"Zacks: 5 Big Drug Stocks That May Continue to Outperform in 2026. Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026. Related tickers mentioned: JNJ, LLY, ^GSPC."},{"id":"ae54b8cb-e6cb-3b02-8df5-c8c7ae9d2fd9","title":"2026 Rate Cuts Coming as Inflation Drops: 5 Quality Dividend Stocks to Buy Now","url":"https://finance.yahoo.com/m/ae54b8cb-e6cb-3b02-8df5-c8c7ae9d2fd9/2026-rate-cuts-coming-as.html","publisher":"24/7 Wall St.","publishedAt":"2025-12-23T12:42:20.000Z","relatedTickers":["GS","LMT","MCD","MDT","XOM"],"mainIdea":"2026 Rate Cuts Coming as Inflation Drops: 5 Quality Dividend Stocks to Buy Now","summary":"24/7 Wall St.: 2026 Rate Cuts Coming as Inflation Drops: 5 Quality Dividend Stocks to Buy Now. Growth and income investors can buy these five top dividend stocks now, tomorrow, next week, or next year and hold for the long term. Related tickers mentioned: GS, LMT, MCD, MDT, XOM."},{"id":"fe028778-39c7-37da-ac77-f90f1de60f08","title":"3 Stocks Estimated To Be Trading Below Fair Value By Up To 46%","url":"https://finance.yahoo.com/news/3-stocks-estimated-trading-below-113755829.html","publisher":"Simply Wall St.","publishedAt":"2025-12-23T11:37:55.000Z","relatedTickers":["COLB","CWBC","FLY","KEY","QXO","SMA","SRAD","UMBF","WGS","^DJI","^GSPC"],"mainIdea":"3 Stocks Estimated To Be Trading Below Fair Value By Up To 46%","summary":"Simply Wall St.: 3 Stocks Estimated To Be Trading Below Fair Value By Up To 46%. As the U.S. stock market continues its upward trajectory, with major indices like the S&P 500 and Dow Jones Industrial Average nearing record highs, investors are increasingly on the lookout for opportunities that may be flying under the radar. In such a climate, identifying stocks that are estimated to be trading below their fair value can offer potential pathways to capitalize on market movements, especially when tech shares lead the charge and precious metals hit fresh records. Related tickers mentioned: COLB, CWBC, FLY, KEY, QXO, SMA, SRAD, UMBF, WGS, ^DJI, ^GSPC."},{"id":"706075f5-de1a-3df5-bab8-3d2de8a2b2a5","title":"What AbbVie (ABBV)'s Restructured OSE Immunology Partnership Means For Shareholders","url":"https://finance.yahoo.com/news/abbvie-abbv-restructured-ose-immunology-231020444.html","publisher":"Simply Wall St.","publishedAt":"2025-12-22T23:10:20.000Z","relatedTickers":["OSE.PA"],"mainIdea":"What AbbVie (ABBV)'s Restructured OSE Immunology Partnership Means For Shareholders","summary":"Simply Wall St.: What AbbVie (ABBV)'s Restructured OSE Immunology Partnership Means For Shareholders. Earlier in December 2025, OSE Immunotherapeutics amended its partnership with AbbVie over the inflammatory disease candidate ABBV-230, with OSE taking back control of preclinical and Phase 1 work, at its own funding risk, while AbbVie kept exclusive rights to later-stage development and commercialization on unchanged economic terms. The revised ABBV-230 arrangement underlines AbbVie’s willingness to lean on partners’ early-stage immunology expertise while reserving control of potential... Related tickers mentioned: OSE.PA."},{"id":"2dc54035-691e-35fa-af3d-c59a4fb8694a","title":"Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends","url":"https://finance.yahoo.com/news/bet-top-ranked-healthcare-etfs-184300571.html","publisher":"Zacks","publishedAt":"2025-12-22T18:43:00.000Z","relatedTickers":["BMY","IHE","JNJ","LLY","PFE","VHCIX","VHT","XLV","^GSPC"],"mainIdea":"Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends","summary":"Zacks: Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends. XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership. Related tickers mentioned: BMY, IHE, JNJ, LLY, PFE, VHCIX, VHT, XLV, ^GSPC."},{"id":"3339d5f8-bcf2-3a23-acee-1a3d745a58ec","title":"Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?","url":"https://finance.yahoo.com/news/invest-invesco-pharmaceuticals-etf-pjp-112002077.html","publisher":"Zacks","publishedAt":"2025-12-22T11:20:02.000Z","relatedTickers":["IVZ","PJP"],"mainIdea":"Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?","summary":"Zacks: Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?. Sector ETF report for PJP Related tickers mentioned: IVZ, PJP."}]}
